EyeGate Pharmaceuticals

EyeGate Pharmaceuticals ROCE

The Return on Capital Employed (ROCE) of EyeGate Pharmaceuticals (EYEG) as of Nov 21, 2026 is -117.29 %. In the previous year, Return on Capital Employed (ROCE) was -107.40 % — a change of 9.20% (lower).

ROCE

-117.29 %

YoY

9.20%

Last updated:

In 2020, EyeGate Pharmaceuticals's return on capital employed (ROCE) was -117.29 %, a 9.20% increase from the -107.40 % ROCE in the previous year.

The EyeGate Pharmaceuticals ROCE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROCE
Date
ROCE
Jan 1, 2014
23.68 USD
Jan 1, 2015
-109.69 USD
Jan 1, 2016
4,045.45 USD
Jan 1, 2017
758.33 USD
Jan 1, 2018
-121.25 USD
Jan 1, 2019
-107.40 USD
Jan 1, 2020
-117.29 USD
The EyeGate Pharmaceuticals ROCE history
YEARROCEYoY
-117.29 %+9.20%
-107.40 %-11.42%
-121.25 %-115.99%
758.33 %-81.25%
4,045.45 %-3,788.15%
-109.69 %-563.28%
23.68 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

EyeGate Pharmaceuticals Stock analysis

What does EyeGate Pharmaceuticals do? EyeGate Pharmaceuticals Inc. is a US pharmaceutical company specializing in the development of ophthalmology products. It was founded in 1998 and is headquartered in Waltham, Massachusetts. The company aims to meet the need for safe and effective therapies for the treatment of eye diseases. Its business model focuses on the development and commercialization of products that enable faster and more effective treatment of eye diseases. The company has two main divisions. The first division includes iontophoretic drug delivery technologies used for the treatment of eye diseases. Iontophoresis is a process in which electric currents are used to transport medications through the skin and into the eyes. EyeGate Pharmaceuticals has developed the EyeGate® II Delivery System technology, which allows for non-invasive, painless, and safe administration of medications into the eye. The EyeGate II Delivery System can be used for the treatment of inflammation, pain, and infections in the eye area. The second division is the development of drugs used for the treatment of eye diseases. EyeGate Pharmaceuticals has several clinical programs in development, including EGP-437, a steroid-free corticosteroid used for the treatment of inflammation of the anterior eye segment. EGP-437 is currently being tested in two clinical trials to demonstrate its efficacy and safety in the treatment of pain and inflammation in the eye. In addition, the company has developed the drug EGP-259 for the treatment of dry eye. EyeGate Pharmaceuticals has previously entered into several partnerships with other companies to further develop and commercialize its technology platform. In 2019, the company entered into a partnership with Valeant Pharmaceuticals International, Inc. to advance the marketing of EGP-437 in the United States. EyeGate Pharmaceuticals aims to continue growing and expanding its presence in the field of ophthalmology in the coming years. The company is working on the development of new products and technologies that enable it to respond to the changing needs and challenges in ophthalmology. Overall, EyeGate Pharmaceuticals is committed to developing and marketing innovative and effective technologies and drugs for the treatment of eye diseases. The company is well positioned to grow in a rapidly evolving market and make a significant contribution to improving the health and quality of life of millions of people worldwide. EyeGate Pharmaceuticals is one of the most popular companies on Eulerpool.

ROCE Details

Unraveling EyeGate Pharmaceuticals's Return on Capital Employed (ROCE)

EyeGate Pharmaceuticals's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing EyeGate Pharmaceuticals's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

EyeGate Pharmaceuticals's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in EyeGate Pharmaceuticals’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about EyeGate Pharmaceuticals stock

Return on Capital Employed (ROCE) of EyeGate Pharmaceuticals is -117.29 % in 2020.

Return on Capital Employed (ROCE) of EyeGate Pharmaceuticals changed from -107.40 % to -117.29 %, representing a 9.20% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Capital Employed (ROCE) EyeGate Pharmaceuticals since 2006 – with annual values, charts, and detailed analysis.

ROCE is a profitability measure and stands for Return on Capital Employed or the return on invested capital. The measure shows the ratio of operating profit to the interest-bearing capital employed. The higher the return on capital employed, the more profitable a company operates and the higher the important free cash flow. The free cash flow refers to the portion of profits that is not needed for expanding the company at the end of a period, but is available to shareholders.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Capital Employed (ROCE)'s EyeGate Pharmaceuticals with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Capital Employed (ROCE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Capital Employed (ROCE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — EyeGate Pharmaceuticals

All Key Metrics — EyeGate Pharmaceuticals